Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12619001412123
ACTRN12619001412123
Active, not recruiting
未知

Preventing relapse of major depressive disorder in youth: RCT of a novel mindfulness-based cognitive online social therapy

Orygen0 sites246 target enrollmentOctober 15, 2019
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Orygen
Enrollment
246
Status
Active, not recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 15, 2019
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Orygen

Eligibility Criteria

Inclusion Criteria

  • •1\.Age 14 to 27 years inclusive;
  • •2\.Ability to read and converse in English;
  • •3\.Ability to provide informed consent;
  • •4\.Ability and willingness to nominate an emergency contact person, such as a close family member;
  • •5\.Diagnosis of MDD (current, partial or full remission) Current or previous primary diagnosis of MDD (corresponding with the most recent episode of care);
  • •6\.\= 1 episode of MDD if in partial remission at time of screening assessment or \= 2 episodes of MDD (including the current episode) if current MDD or MDD in full remission at time of screening assessment.

Exclusion Criteria

  • •1\.Inability to converse in, or read English;
  • •2\.Acute risk of self\-harm requiring urgent intervention (i.e., suicidal ideation with a current plan and intent to enact this plan);
  • •3\.A diagnosed permanent developmental delay or intellectual disability;
  • •4\.Current or past episode of mania or hypomania;
  • •5\.Previous exposure to a MOST platform.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Relapse prevention in patients with major depression treated with electroconvulsive therapy using a fixed dose range of escitalopram compared to a fixed dose of nortriptyline (DUAG-7)A randomised controlled 6 month double-blind study - Relapse prevention with escitalopram or nortriptyline following ECT (DUAG-7)
EUCTR2008-003877-42-DKDanish University Antidepressant Group (DUAG)300
Not yet recruiting
Not Applicable
Reducing relapse and recurrence in depression with continuation Cognitive Therapy: a randomized controlled trial.depressive disorderdepression10027946
NL-OMON40027Arkin (Amsterdam)214
Active, not recruiting
Phase 4
Antidepressants to prevent relapse in depression in older people aged 75 years and overDepressionMental and Behavioural Disorders
ISRCTN26190474niversity College London430
Completed
Not Applicable
Trial platform: preventing depression relapse in the National Health Service practice using Mindfulness-Based Cognitive Therapy
ISRCTN12720810niversity of Exeter (UK)80
Active, not recruiting
Not Applicable
Preventing depression relapse / recurrence in NHS settings through mindfulness-based cognitive therapy (MBCT). - PREVENT
EUCTR2009-012428-10-GBniversity of Exeter420